Merck and Eisai's experimental combination treatment helped extend the time certain patients with advanced kidney cell cancer ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN ANTONIO -- ...
Merck MRK along with partner Eisai announced data from the phase III LEAP-015 study, which evaluated blockbuster PD-1 inhibitor, Keytruda (pembrolizumab) and Eisai’s TKI inhibitor, Lenvima (lenvatinib ...
Venetoclax improved PFS but not OS in relapsed/refractory multiple myeloma, with significant benefits in t(11;14) and/or BCL2high subgroups. The overall response rate was higher with venetoclax, and ...
The ORR with the combination was 19.0%, which surpassed the historical benchmark of 14.6% (P=0.0787), but failed to beat an ORR of ≥21% (one-sample z-test P≤0.0245) that was required to demonstrate ...
The industry appetite for waterproof and ingress protection features is increasing. In keeping with this trend, Positronic has produced the WCBD Series, a waterproof version of the popular Combo-D ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback